FORT LAUDERDALE, Fla., Oct. 5, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the appointment of James P. Mc Menamy as Vice President, Commercialization. In this role, Mr. Mc Menamy will be responsible for leading Vigilant Biosciences' strategic commercialization efforts in the global market, as the Company continues to advance its oral cancer risk assessment system towards commercialization.
Mr. Mc Menamy brings more than 25 years of experience in the professional biomedical/diagnostics community to his role at Vigilant Biosciences, with specific expertise in worldwide in-vitro point-of-care diagnostics instrumentation and disposables. Most recently, Mr. Mc Menamy served as the Vice President of Business and Product Development at SCIL Animal Care Company, GmbH, which was recently acquired by Henry Schein, Inc. In this role, Mr. Mc Menamy was responsible for development and implementation of a worldwide laboratory clinical instrumentation new product and business growth strategy. Previously, Mr. Mc Menamy held the position of Vice President, Marketing and Sales at Nexus-Dx, a subsidiary of SAMSUNG Electronics, executing the US launch and European launch of a portfolio of point-of-care diagnostic instrument systems for the medical markets. Additionally, Mr. Mc Menamy's experiences include Vice President and General Manager of the rapid point-of-care diagnostics segment at Alfa Scientific Designs, and Vice President for Distribution Relations for the North American Clinical Diagnostics Business Unit of Inverness Medical Innovations, which was subsequently acquired by Alere, Inc. Mr. Mc Menamy has also held positions at ACON Laboratories and QUIDEL Corporation.
"We are thrilled to welcome James, an esteemed marketing professional, to our Leadership team," said Matthew H.J. Kim, Founder, Chairman and CEO of Vigilant Biosciences, Inc. "His background and extensive, prior experience will bring enormous value to Vigilant Biosciences in our efforts to advance the OncAlert oral cancer risk assessment system towards commercialization, in both the U.S. and abroad."
Mr. Mc Menamy received his BS degree from the N.Y. Institute of Technology and his MBA in Marketing and Health Administration from Rutgers University.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. The Vigilant Biosciences™ OncAlert™ point-of-care and lab assay products are currently undergoing the CE Mark registration approval process and not yet available for sale in any market at this time. For more information, visit www.vigilantbiosciences.com.